预约演示
更新于：2026-06-09
Voglibose
伏格列波糖
更新于：2026-06-09
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C10H21NO7 |
InChIKeyFZNCGRZWXLXZSZ-CIQUZCHMSA-N |
CAS号83480-29-9 |
关联
60
项与 伏格列波糖 相关的临床试验CTR20252676
伏格列波糖口崩片人体生物等效性研究
CTR20244400
伏格列波糖口崩片在中国健康受试者中单次口服给药的一项单中心、随机、开放、两制剂、两序列生物等效性试验
CTR20243825
伏格列波糖片人体生物等效性研究
100 项与 伏格列波糖 相关的临床结果
登录后查看更多信息
100 项与 伏格列波糖 相关的转化医学
登录后查看更多信息
100 项与 伏格列波糖 相关的专利（医药）
登录后查看更多信息
539
项与 伏格列波糖 相关的文献（医药）2026-05-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Design, synthesis of novel methyl-glycosyl furanose based sulfonium type α-glucosidase inhibitors with potent antihyperglycemic activity
Article
作者: Xu, Bohang ; Xie, Weijia ; Tanabe, Genzoh ; Li, Yaojia ; Li, Wei ; Yao, Xuesong ; Li, Yu ; Sun, Xiaolian ; He, Xiaosong ; Muraoka, Osamu ; Jin, Shuqing
Developing effective α-glucosidase inhibitors is critical for managing hyperglycemia in individuals with high-carbohydrate diets; however, current drugs exhibit limitations in both efficacy and tolerability. In the present study, 25 derivatives of neoponkoranol, an active sulfonium type α-glucosidase inhibitor identified from Genus Salacia were synthesized. These compounds containing a methyl-glycosyl furanose scaffold modified with various hydrophobic groups at the 5'-O-position, were characterized using HRMS and NMR spectroscopy. Biological evaluations demonstrated a selectively enhanced maltase inhibition profile while maintaining broad-spectrum activity. Most sulfonium salts exhibited potent inhibitory activity against maltase and sucrase with IC50 values ranging from 0.14 to 2.21 μM; these potencies are comparable to or superior to those of the positive controls acarbose and voglibose. In addition, the designed derivatives also exhibited strong isomaltase inhibitory activities whereas acarbose was almost inactive against this enzyme. Compound LY-23 emerged as the most potent inhibitor with maltase IC50 = 0.18 ± 0.03 μM, sucrase IC50 = 0.14 ± 0.01 μM, and isomaltase IC50 = 0.51 ± 0.06 μM. Mechanism studies characterized LY-23 as a competitive inhibitor. Molecular docking along with 3D fluorescence and CD spectral analyses indicated that LY-23 binds to α-glucosidase, inducing secondary structural and conformational changes in the enzyme. Furthermore, LY-23 showed no significant cytotoxicity in HEK293T and L02 cells. Remarkably, in vivo studies revealed that the oral administration of LY-23 (1.0 or 10.0 mg/kg) effectively reduced postprandial blood glucose levels in normal ICR mice following maltose or sucrose loading, with an efficacy comparable to that of voglibose (1.0 mg/kg) and acarbose (20.0 mg/kg), respectively. These findings highlight LY-23 as a promising candidate for the development of novel α-glucosidase inhibitors with antihyperglycemic properties.
2026-04-06Cureus Journal of Medical Science
Effectiveness of Nutritional Therapy Versus Alpha-Glucosidase Inhibitors in Postprandial Glycemia Control in an Indian Subpopulation of Patients With Type 2 Diabetes: A Prospective Crossover Study
Article
作者: Hanchinal, Shivaraj S ; Shambhukari, Praveen Rao ; Gaddam, Anudeep
BACKGROUND:
Type 2 diabetes mellitus (T2DM) poses a significant global health challenge, impacting millions of people worldwide. While many studies focus on HbA1c levels, there remains a need to evaluate glycemic variability and postprandial glucose (PPG) excursions. Therefore, this study was conducted to assess and compare the safety and effectiveness of nutritional therapy and alpha-glucosidase inhibitors in achieving rapid PPG stabilization in an Indian subpopulation of patients with T2DM.
METHODS:
This short-term open-label study included T2DM patients uncontrolled on metformin and sulfonylurea. The study enrolled 60 participants (40 males, 20 females) with a mean age of 54.06 ± 6.04 years, with the majority being 30-60 years of age (85%). All patients were given intermittent medical nutritional therapy (low glycemic index (LGI) diet) and alpha-glucosidase inhibitors (AGIs; acarbose, voglibose) to manage postprandial glycemia. A rotational design ensured that each group experienced all interventions in varying sequences for a comprehensive analysis of their effects. Glycemic responses were assessed using finger-stick capillary glucose measurements and continuous glucose monitoring (CGM) to evaluate postprandial and 24-hour glycemic variability.
RESULTS:
Postprandial mean glucose levels were significantly reduced with all interventions (p<0.05), with the highest reduction observed with acarbose. Between AGIs, the adverse effects were similar between medications. The 24-hour mean glucose levels, mean amplitude of glycemic excursion, and area under the curve for 24-hour glycemic fluctuations were significantly lower with interventions, especially acarbose.
CONCLUSION:
We conclude that AGIs and LGI diets effectively reduce postprandial glucose, especially in Indian T2DM patients consuming high-carbohydrate diets with a high glycemic load.
2026-04-01Journal of Diabetes
Efficacy and Safety of Glimepiride, Voglibose, and Metformin
ER
in Type 2 Diabetes: A Randomized, Active‐Controlled Study
Article
作者: Saran, Sanjay ; Kudugunti, Neelaveni ; Joglekar, Sadhna ; Mehta, Suyog ; Patel, Piyush ; Behera, Sapan ; Shaikh, Raisa ; Kanungo, Alok ; Kurmi, Prakash Harishchandra ; Kumar, S. Vasanth ; Patil, Dipak ; Kashinath, Preetam Ahirrao ; Ghadge, Pravin ; Parmar, Kartikeya ; Gupta, Sandeep Kumar ; Lakhwani, Lalit ; Arya, Vivek Vedprakash ; Mohan, Brij ; Ramanathan, Balamurugan ; Patel, Micky ; Das, Bharat
ABSTRACT:
Background:
India ranks second in the global diabetes epidemic, with about 89 million individuals living with Type 2 diabetes mellitus (T2DM). We compared the efficacy and safety of fixed‐dose combination (FDC) of glimepiride, voglibose, and extended‐release metformin (GLIME+VOGLI+MET‐ER) with voglibose and metformin (VOGLI+MET) and glimepiride and metformin (GLIME+MET).
Methods:
A Phase IV, randomized, open‐label, active‐controlled study was performed in adult patients with T2DM poorly controlled with metformin. Patients received twice daily doses of GLIME+VOGLI+MET‐ER (1 + 0.2 + 500 mg: Trivolib 1, 2 + 0.2 + 500 mg: Trivolib 2); or VOGLI+MET (0.2 + 500 mg, 0.3 + 500 mg) or GLIME+MET (1 + 500 mg, 2 + 500 mg). The primary endpoint was the change in HbA1c from baseline.
Results:
Of the 458 patients screened, 399 were randomized (GLIME+VOGLI+MET‐ER [
n
= 133], VOGLI+MET (
n
= 135), and GLIME+MET [
n
= 131]). The mean baseline HbA1c was ~8.35% (~67.77 mmol/mol). All the treatments showed a significant reduction in HbA1c at Weeks 12 and 24. Mean change in % (mmol/mol) HbA1c was significantly more with GLIME+VOGLI+MET‐ER versus VOGLI+MET and GLIME+MET at Week 12 (−1.02 ± 0.60 [−11.2 ± 6.52] vs. −0.68 ± 0.64 [−7.49 ± 6.95],
p
< 0.001 and −0.88 ± 0.49 [−9.65 ± 5.34],
p
= 0.0154) and Week 24 (−1.57 ± 0.74 [−17.2 ± 8.14] vs. −1.11 ± 0.80 [−12.2 ± 8.79],
p
< 0.001 and −1.28 ± 0.60 [−14.0 ± 6.56],
p
= 0.0002). Overall, 49 adverse events (AEs) were reported in 32/399 (8.0%) patients. One patient each in GLIME+VOGLI+MET‐ER and VOGLI+MET groups had level 1 hypoglycemia requiring no management. No severe or serious AEs were reported.
Conclusions:
In adult patients with T2DM inadequately controlled on metformin monotherapy, GLIME+VOGLI+MET‐ER demonstrated superior HbA1c reduction compared with VOGLI+MET and GLIME+MET at Weeks 12 and 24. Study medications were safe and well‐tolerated.Trial Registration:
Clinical Trial Registry India—CTRI/2020/11/029080 [Registered on: 12/11/2020].
100 项与 伏格列波糖 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病 | 中国 | 2001-01-01 | |
| 糖尿病 | 中国 | 2001-01-01 | |
| 2型糖尿病 | 日本 | 1994-07-01 | |
| 高血糖 | 日本 | 1994-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 葡萄糖耐受不良 | 临床阶段不明 | 中国 | 2008-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 494 | 膚膚憲選鏇衊範繭鏇願(鬱鑰選鏇壓願憲窪顧廠) = 壓獵壓窪夢鹽壓鏇襯膚 獵廠選艱積築夢餘淵繭 (積糧醖憲鏇夢鑰範鑰遞, 0.0742) 更多 | - | 2019-02-04 | |||
膚膚憲選鏇衊範繭鏇願(鬱鑰選鏇壓願憲窪顧廠) = 襯醖鹽壓廠襯構蓋廠觸 獵廠選艱積築夢餘淵繭 (積糧醖憲鏇夢鑰範鑰遞, 0.0764) 更多 | |||||||
临床4期 | 197 | 壓鏇壓艱醖築衊襯鬱鏇 = 積襯積築齋簾鹹醖醖餘 築壓獵齋鑰淵構顧積憲 (襯簾選積壓壓遞觸觸鹽, 齋鏇鑰憲夢願鏇艱夢鏇 ~ 膚蓋蓋壓選餘壓築醖簾) 更多 | - | 2015-04-09 | |||
临床1期 | - | 22 | Metformin | 糧廠簾襯網窪鏇蓋夢廠(範衊範衊鏇蓋鑰膚願淵): geometric mean ratio = 0.99 (90% CI, 0.92 ~ 1.06), P-Value = > 0.05 更多 | - | 2014-11-01 | |
Metformin + Voglibose | |||||||
临床3期 | 133 | Sitagliptin 50 mg/day | 醖窪襯衊鏇選製築鬱淵(鬱願獵壓壓窪膚襯淵糧) = 觸範鏇壓廠窪獵糧繭壓 淵襯構願顧選膚壓願繭 (窪淵鹽壓築繭鏇鹽選餘 ) 更多 | - | 2013-11-27 | ||
临床3期 | 319 | Sitagliptin 50 mg once daily | 繭窪鏇鏇網醖遞餘襯廠(艱廠範膚廠壓繭觸憲獵) = 願鹹鏇簾觸艱構觸糧艱 鑰繭鏇憲廠壓鬱艱餘艱 (選蓋淵積網鏇夢蓋鬱糧, -0.8 ~ -0.6) 更多 | 积极 | 2010-07-01 | ||
Voglibose 0.2 mg thrice daily | 繭窪鏇鏇網醖遞餘襯廠(艱廠範膚廠壓繭觸憲獵) = 選衊廠鹹獵糧選網積範 鑰繭鏇憲廠壓鬱艱餘艱 (選蓋淵積網鏇夢蓋鬱糧, -0.4 ~ -0.2) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用